Windtree Therapeutics, Inc. is a biotechnology company focused on developing novel KL4 surfactant therapies for respiratory diseases and other potential applications. The Company's proprietary technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant ) that is structurally similar to human pulmonary surfactant — and novel drug-delivery technologies that are being developed to enable noninvasive administration of aerosolized KL4 surfactant. Windtree is focused initially on improving the management of respiratory distress syndrome (RDS) in premature infants as surfactant therapy has been shown to save lives in this condition. The Company believes that its proprietary technologies may make it possible, over time, to develop a pipeline of KL4 surfactant product candidates to address a variety of respiratory diseases for which there are few or no approved therapies and, in doing so, potentially deliver a lifetime of hope to patients and their families.